- Home
- CTBI vs AUPH Comparison
CTBI vs AUPH Comparison
Compare CTBI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTBI
- AUPH
- Stock Information
- Founded
- CTBI 1903
- AUPH 1993
- Country
- CTBI United States
- AUPH Canada
- Employees
- CTBI N/A
- AUPH N/A
- Industry
- CTBI Major Banks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CTBI Finance
- AUPH Health Care
- Exchange
- CTBI Nasdaq
- AUPH Nasdaq
- Market Cap
- CTBI 922.9M
- AUPH 999.8M
- IPO Year
- CTBI N/A
- AUPH 1999
- Fundamental
- Price
- CTBI $48.82
- AUPH $8.18
- Analyst Decision
- CTBI Buy
- AUPH Strong Buy
- Analyst Count
- CTBI 2
- AUPH 2
- Target Price
- CTBI $57.00
- AUPH $11.50
- AVG Volume (30 Days)
- CTBI 68.6K
- AUPH 1.3M
- Earning Date
- CTBI 04-16-2025
- AUPH 05-05-2025
- Dividend Yield
- CTBI 3.83%
- AUPH N/A
- EPS Growth
- CTBI 10.88
- AUPH N/A
- EPS
- CTBI 4.79
- AUPH 0.04
- Revenue
- CTBI $244,136,000.00
- AUPH $235,133,000.00
- Revenue This Year
- CTBI $17.58
- AUPH $11.86
- Revenue Next Year
- CTBI $3.48
- AUPH $24.96
- P/E Ratio
- CTBI $10.30
- AUPH $204.50
- Revenue Growth
- CTBI 10.52
- AUPH 33.97
- 52 Week Low
- CTBI $40.19
- AUPH $4.86
- 52 Week High
- CTBI $61.67
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- CTBI 49.31
- AUPH 56.33
- Support Level
- CTBI $46.33
- AUPH $7.92
- Resistance Level
- CTBI $50.40
- AUPH $8.32
- Average True Range (ATR)
- CTBI 1.78
- AUPH 0.34
- MACD
- CTBI 0.43
- AUPH 0.07
- Stochastic Oscillator
- CTBI 72.76
- AUPH 90.64
About CTBI Community Trust Bancorp Inc.
Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and southcentral Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.